Skip to main content
Father's Day Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

Bayer's asundexian starts EU review for ischaemic stroke

Summary by Pharmaphorum
The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.

3 Articles

PharmaphorumPharmaphorum
Center

Bayer's asundexian starts EU review for ischaemic stroke

The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.

Read Full Article
Verdict HospitalVerdict Hospital
Reposted by
Pharmaceutical Business reviewPharmaceutical Business review

EMA validates Bayer's asundexian application for ischaemic stroke

The EMA has validated Bayer's marketing authorisation application for asundexian, an oral Factor XIa inhibitor, to prevent ischaemic stroke.The post EMA validates Bayer’s asundexian application for ischaemic stroke appeared first on Hospital Management.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Pharmaphorum broke the news on Wednesday, June 10, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

European Union icon

European Union

Johnson & Johnson icon

Johnson & Johnson

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal